[go: up one dir, main page]

AR103162A1 - Anticuerpos anti-c5 y métodos para su uso - Google Patents

Anticuerpos anti-c5 y métodos para su uso

Info

Publication number
AR103162A1
AR103162A1 ARP150104181A ARP150104181A AR103162A1 AR 103162 A1 AR103162 A1 AR 103162A1 AR P150104181 A ARP150104181 A AR P150104181A AR P150104181 A ARP150104181 A AR P150104181A AR 103162 A1 AR103162 A1 AR 103162A1
Authority
AR
Argentina
Prior art keywords
application
antibody
present application
provides
antibodies
Prior art date
Application number
ARP150104181A
Other languages
English (en)
Inventor
Ruike Yoshinao
Sampei Zenjiro
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR103162A1 publication Critical patent/AR103162A1/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4716Complement proteins, e.g. anaphylatoxin, C3a, C5a

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Rehabilitation Therapy (AREA)

Abstract

Un objetivo de la solicitud es proveer anticuerpos anti-C5 y métodos para su uso. La solicitud provee anticuerpos anti-C5 y métodos para su uso. En algunas formas de realización, un anticuerpo anti-C5 aislado de la presente solicitud se une a un epitope dentro de la cadena b de C5 con mayor afinidad a un pH neutro que a un pH ácido. La solicitud también provee ácidos nucleicos aislados que codifican un anticuerpo anti-C5 de la presente solicitud. La solicitud también provee células huésped que comprenden un ácido nucleico de la presente solicitud. La solicitud también provee un método para producir un anticuerpo que comprende cultivar una célula huésped de la presente solicitud a fin de producir el anticuerpo. La solicitud provee además un método para producir un anticuerpo anti-C5 que comprende inmunizar un animal contra un polipéptido que comprende el dominio MG1-MG2 de la cadena b de C5. Los anticuerpos anti-C5 de la presente solicitud se pueden usar como medicamento. Reivindicación 23: Un anticuerpo caracterizado porque comprende una secuencia de VH de cualquiera de las SEQ ID Nº 10, 106 - 110 y una secuencia de VL de cualquiera de las SEQ ID Nº 20, 111 - 113.
ARP150104181A 2014-12-19 2015-12-18 Anticuerpos anti-c5 y métodos para su uso AR103162A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014257647 2014-12-19

Publications (1)

Publication Number Publication Date
AR103162A1 true AR103162A1 (es) 2017-04-19

Family

ID=56126263

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150104181A AR103162A1 (es) 2014-12-19 2015-12-18 Anticuerpos anti-c5 y métodos para su uso

Country Status (30)

Country Link
US (5) US9765135B2 (es)
EP (2) EP3233921B1 (es)
JP (2) JP6174782B2 (es)
KR (3) KR20230044338A (es)
CN (2) CN113045650A (es)
AR (1) AR103162A1 (es)
AU (1) AU2015365167B2 (es)
BR (1) BR112017011235A2 (es)
CA (1) CA2967554A1 (es)
CL (2) CL2017001585A1 (es)
CO (1) CO2017006651A2 (es)
CR (1) CR20170251A (es)
EA (1) EA201791366A1 (es)
ES (1) ES2899894T3 (es)
HR (1) HRP20211934T1 (es)
HU (1) HUE056489T2 (es)
LT (1) LT3233921T (es)
MX (1) MX384138B (es)
MY (1) MY183415A (es)
PH (1) PH12017501114B1 (es)
PL (1) PL3233921T3 (es)
PT (1) PT3233921T (es)
RS (1) RS62749B1 (es)
RU (1) RU2746356C2 (es)
SG (2) SG10201710322VA (es)
SI (1) SI3233921T1 (es)
TW (3) TWI725847B (es)
UA (1) UA128712C2 (es)
WO (1) WO2016098356A1 (es)
ZA (1) ZA201703241B (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
EP2708559B1 (en) 2008-04-11 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI654204B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
WO2012115241A1 (ja) 2011-02-25 2012-08-30 中外製薬株式会社 FcγRIIb特異的Fc抗体
TW201817744A (zh) * 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
CN104093424A (zh) 2011-09-30 2014-10-08 中外制药株式会社 诱导针对靶抗原的免疫应答的抗原结合分子
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CN113416256A (zh) 2011-11-30 2021-09-21 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
JP6226752B2 (ja) 2012-02-09 2017-11-08 中外製薬株式会社 抗体のFc領域改変体
CN104487457B (zh) 2012-05-30 2018-01-26 中外制药株式会社 靶组织特异性抗原结合分子
RU2729831C2 (ru) 2012-08-24 2020-08-12 Чугаи Сейяку Кабусики Кайся ВАРИАНТЫ FcγRIIB-СПЕЦИФИЧЕСКОЙ Fc-ОБЛАСТИ
KR20210130260A (ko) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Fc영역 개변체
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
ES2899894T3 (es) 2014-12-19 2022-03-15 Chugai Pharmaceutical Co Ltd Anticuerpos anti-C5 y métodos de uso
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
EP3390442B1 (en) * 2015-12-18 2023-11-08 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3402816A1 (en) 2016-01-11 2018-11-21 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
JP7181091B2 (ja) 2016-05-10 2022-11-30 ジェネンテック, インコーポレイテッド ポリペプチドの組み換え産生中にトリスルフィド結合を減少させる方法
EP3909609A1 (en) 2016-05-27 2021-11-17 Alexion Pharmaceuticals, Inc. Methods for treatment of refractory generalized myasthenia gravis
KR102667023B1 (ko) 2016-06-14 2024-05-21 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
TWI610941B (zh) * 2016-06-17 2018-01-11 Chugai Seiyaku Kabushiki Kaisha 抗c5抗體及使用方法
TWI831965B (zh) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
US20190328854A1 (en) * 2016-08-29 2019-10-31 The Cleveland Clinic Foundation C5 immunization for autologous anti-c5 antibody production
US20190330319A1 (en) * 2016-12-16 2019-10-31 Samsung Bioepis Co., Ltd Stable aqueous anti-c5 antibody composition
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
CR20220563A (es) * 2017-01-31 2022-12-07 Chugai Pharmaceutical Co Ltd Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
WO2018165062A1 (en) * 2017-03-06 2018-09-13 The Trustees Of The University Of Pensylvania Anti-c5 antibodies and uses thereof
ES2967965T3 (es) 2017-05-22 2024-05-06 Alexion Pharma Inc Dosis y administración de anticuerpos anti-C5 para el tratamiento de enteropatía pierde-proteínas en pacientes
CN111315411B (zh) 2017-07-27 2023-02-28 瑞颂医药公司 高浓度抗c5抗体制剂
BR112020008182A2 (pt) 2017-10-26 2020-10-27 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
CN111556895B (zh) * 2017-11-14 2024-09-13 中外制药株式会社 抗-c1s抗体及使用方法
SG11202004662RA (en) 2017-12-13 2020-06-29 Regeneron Pharma Anti-c5 antibody combinations and uses thereof
WO2019191552A1 (en) 2018-03-29 2019-10-03 Genentech, Inc. Modulating lactogenic activity in mammalian cells
CN112292601B (zh) * 2018-05-24 2024-07-02 西格马-奥尔德里奇有限责任公司 蛋白定量分析
WO2019231983A1 (en) 2018-05-31 2019-12-05 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
JP7577542B2 (ja) 2018-06-04 2024-11-05 アレクシオン ファーマシューティカルズ, インコーポレイテッド 小児患者における非典型溶血性尿毒症症候群(aHUS)の治療のための抗C5抗体の用量および投与
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
TWI704157B (zh) * 2018-08-01 2020-09-11 日商中外製藥股份有限公司 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法
BR112021004141A2 (pt) * 2018-09-06 2021-05-25 The Trustees Of The University Of Pennsylvania anticorpo dependente de ph que se liga especificamente a c5 humano, métodos para tratar uma doença ou distúrbio mediado pela via do complemento em um indivíduo e para reduzir a atividade de um sistema complemento de um indivíduo, célula, e, animal não humano geneticamente modificado.
JP2022500427A (ja) * 2018-09-17 2022-01-04 国立大学法人京都大学 肝傷害又は肝不全の処置のための抗c5剤の投与
US20200095307A1 (en) 2018-09-21 2020-03-26 Alexion Pharmaceuticals, Inc. Compositions and methods for the treatment of neuromyelitis optica
US20210388070A1 (en) 2018-10-30 2021-12-16 Alexion Pharmaceuticals, Inc. Co-administration of a hyaluronidase and anti-c5 antibody for treatment of complement-associated conditions
MX2021004994A (es) 2018-10-30 2021-06-15 Alexion Pharma Inc Dosificacion subcutanea y administracion de anticuerpos anti-c5 para el tratamiento de la hemoglobinuria paroxistica nocturna (pnh).
HUE067202T2 (hu) 2019-01-25 2024-10-28 Alexion Pharma Inc Anti-C5 antitestek dózisa és beadása atípusos hemolitikus urémiás szindróma (aHUS) kezelésére
KR20210126045A (ko) 2019-02-14 2021-10-19 알렉시온 파마슈티칼스, 인코포레이티드 전신 중증 근무력증을 치료하기 위한 항-c5 항체의 투여량 및 투여
BR112021019571A2 (pt) 2019-04-19 2021-12-07 Chugai Pharmaceutical Co Ltd Receptor quimérico que reconhece o sítio de modificação do anticorpo
WO2020213706A1 (en) * 2019-04-19 2020-10-22 Chugai Seiyaku Kabushiki Kaisha Antibodies and compositions for use in detecting or capturing a polypeptide in a sample, and methods for detecting or capturing a polypeptide in a sample
AU2020275348A1 (en) 2019-05-15 2021-12-09 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
US20220227851A1 (en) 2019-05-24 2022-07-21 Alexion Pharmaceuticals, Inc. Methods of treating vitiligo using an anti-c5 antibody
JP7437260B2 (ja) 2019-07-31 2024-02-22 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 抗c5抗体クロバリマブの使用によるc5関連疾患の治療または予防のための薬用量および投与レジメン
EP4003409A1 (en) 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
US20220356234A1 (en) 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
CA3161271A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Anti-c5 antibody for the treatment of neuromyelitis optica spectrum disorder
US20230043576A1 (en) 2019-12-23 2023-02-09 Alexion Pharmaceuticals, Inc. Methods of treating pregnancy-associated atypical hemolytic uremic syndrome using an anti-c5 antibody
CN111234016B (zh) * 2020-02-23 2021-09-07 北京康普美特创新医药科技有限责任公司 一种抗补体c5分子的全人源单克隆抗体及应用
US12098365B2 (en) 2020-03-26 2024-09-24 Genentech, Inc. Modified mammalian cells
EP4126970A4 (en) 2020-03-31 2024-05-01 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PRODUCING MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES
CN113563467A (zh) * 2020-04-28 2021-10-29 上海普铭生物科技有限公司 针对人补体蛋白c5的抗体及其应用
BR112022022980A2 (pt) 2020-05-12 2022-12-20 Alexion Pharma Inc Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna
EP4150338A1 (en) 2020-05-15 2023-03-22 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
CA3183934A1 (en) * 2020-05-29 2021-12-02 Amgen Inc. Antibody formulations and uses thereof
JP7674399B2 (ja) * 2020-06-24 2025-05-09 スタイドソン・(ベイジン)・バイオファーマシューティカルズ・カンパニー・リミテッド C5aを特異的に認識する抗体およびその使用
EP4172192A1 (en) 2020-06-24 2023-05-03 Genentech, Inc. Apoptosis resistant cell lines
CA3173011A1 (en) 2020-06-24 2021-12-30 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions
WO2022011086A1 (en) 2020-07-09 2022-01-13 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
MX2023001702A (es) 2020-08-13 2023-03-09 Alexion Pharma Inc Dosificacion y administracion de anticuerpos anti-c5 para el tratamiento de la microangiopatia trombotica asociada al trasplante de celulas madre hematopoyeticas (hsct-tma).
TW202227625A (zh) 2020-08-28 2022-07-16 美商建南德克公司 宿主細胞蛋白質之CRISPR/Cas9多重剔除
EP4213940A1 (en) 2020-09-21 2023-07-26 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating c5-mediated glomerular nephritis (gn), including lupus nephritis (ln) and/or iga nephropathy (igan)
CA3196434A1 (en) 2020-10-23 2022-04-28 Krista K. JOHNSON Methods of treating patients having complement disorders using anti-c5 antibodies
CA3173016A1 (en) 2021-01-22 2022-07-28 Gin-Fu CHEN Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody
EP4326855A1 (en) 2021-04-19 2024-02-28 Genentech, Inc. Modified mammalian cells
JP2024521107A (ja) 2021-05-21 2024-05-28 ジェネンテック, インコーポレイテッド 目的の組換え産物を産生するための修飾細胞
TW202306994A (zh) 2021-06-04 2023-02-16 日商中外製藥股份有限公司 抗ddr2抗體及其用途
WO2022265915A1 (en) 2021-06-14 2022-12-22 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating dermatomyositis (dm)
US12448451B2 (en) 2021-06-25 2025-10-21 Chugai Seiyaku Kabushiki Kaisha Anti-CTLA-4 antibody and use thereof
JP7472405B2 (ja) * 2021-06-25 2024-04-22 中外製薬株式会社 抗ctla-4抗体
WO2023287991A1 (en) 2021-07-14 2023-01-19 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of myasthenia gravis
WO2023023220A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using a complement alternative pathway inhibitor
TW202346339A (zh) 2022-04-04 2023-12-01 瑞士商赫孚孟拉羅股份公司 藉由使用抗c5抗體克羅伐單抗之治療或預防格林-巴利症候群之劑量及投予方案
TW202404632A (zh) 2022-04-04 2024-02-01 瑞士商赫孚孟拉羅股份公司 用於藉由使用抗c5抗體克羅伐單抗治療或預防格林-巴利症候群之劑量及投予方案
US20260022164A1 (en) * 2022-05-04 2026-01-22 Alexion Pharmaceuticals, Inc. Compositions and methods for the treatment of neuromyelitis optica spectrum disorder
TW202426048A (zh) 2022-09-06 2024-07-01 美商阿雷希昂製藥公司 用於治療造血幹細胞移植相關血栓性(hsct-tma)的抗c5抗體的補充劑量和投與
WO2024054436A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)
TW202423479A (zh) 2022-09-28 2024-06-16 美商阿雷希昂製藥公司 用於預防或最小化患有慢性腎病的患者中的心臟手術相關急性腎損傷(csa-aki)和/或隨後的主要不良腎事件(make)的抗c5抗體之劑量及投與
WO2024238422A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of a panel of lectins for detection of complement biomarkers in urine extracellular vesicles
WO2024238421A1 (en) 2023-05-12 2024-11-21 Alexion Pharmaceuticals, Inc. Use of biomarkers for the identification and treatment of complement-mediated disorders
WO2025006898A1 (en) * 2023-06-29 2025-01-02 Beam Therapeutics Inc. Anti-idiotypic antibodies to cluster of differentiation 7-targeted binding domains and related compositions and methods
WO2025045251A2 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Multispecific constructs comprising anti-factor d moiety
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
WO2025166118A1 (en) 2024-02-02 2025-08-07 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treating iga nephropathy (igan)
WO2025221479A1 (en) 2024-04-16 2025-10-23 Alexion Pharmaceuticals, Inc. Biomarkers for monitoring effective treatment of neuromyelitis optica spectrum disorder (nmosd) with complement component c5 inhibitors

Family Cites Families (276)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE370449B (es) 1970-08-29 1974-10-14 Philips Nv
JPS5824836B2 (ja) 1974-10-14 1983-05-24 ノウミボウサイコウギヨウ カブシキガイシヤ カサイナドノツウホウソウチ
US4769320A (en) 1982-07-27 1988-09-06 New England Medical Center Hospitals, Inc. Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations
ES8404858A1 (es) 1982-04-12 1984-05-16 Hybritech Inc Un procedimiento para la purificacion de un anticuerpo.
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
JPS6350741A (ja) 1986-08-20 1988-03-03 Nippon Tectron Co Ltd 蛍光偏光分析装置
JPH06104071B2 (ja) 1986-08-24 1994-12-21 財団法人化学及血清療法研究所 第▲ix▼因子コンホメ−シヨン特異性モノクロ−ナル抗体
US4801687A (en) 1986-10-27 1989-01-31 Bioprobe International, Inc. Monoclonal antibody purification process using protein A
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5322678A (en) 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5202253A (en) 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
CA2006684C (en) 1988-12-30 1996-12-17 Charles T. Esmon Monoclonal antibody against protein c
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
JPH0636741B2 (ja) 1989-11-08 1994-05-18 帝人株式会社 ヒト・プロテインcの分離方法
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2075927A1 (en) 1990-02-16 1991-08-17 Victor A. Raso Hybrid reagents capable of selectively releasing molecules into cells
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1994029471A1 (en) 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US6309636B1 (en) 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
PL186506B1 (pl) 1994-10-07 2004-01-30 Chugai Pharmaceutical Co Ltd Sposób wytwarzania środka farmaceutycznego hamującego wzrost komórek błony maziowej i zastosowanie monoklonalnego przeciwciała
DE4436561C1 (de) 1994-10-13 1996-03-14 Deutsche Spezialglas Ag Verfahren zur Veränderung der Durchbiegung von anodisch gebondeten flächigen Verbundkörpern aus Glas und Metall oder Halbleitermaterialien
HU225392B1 (en) 1994-10-21 2006-11-28 Chugai Pharmaceutical Co Ltd Use of an antibody againts interleukin-6-receptor for producing a pharmaceutical composition for treating anemia and cachexia caused by il-6 production
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US6485943B2 (en) 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5830478A (en) 1995-06-07 1998-11-03 Boston Biomedical Research Institute Method for delivering functional domains of diphtheria toxin to a cellular target
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1998003546A1 (en) 1996-07-19 1998-01-29 Amgen Inc. Analogs of cationic proteins
US5990286A (en) 1996-12-18 1999-11-23 Techniclone, Inc. Antibodies with reduced net positive charge
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US7365166B2 (en) 1997-04-07 2008-04-29 Genentech, Inc. Anti-VEGF antibodies
AU7132798A (en) 1997-04-17 1998-11-11 Amgen, Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU757627B2 (en) 1997-06-24 2003-02-27 Genentech Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
AU750453B2 (en) 1997-10-03 2002-07-18 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
JP2001521909A (ja) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド 糖タンパク質グリコフォームを含む方法及び組成物
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
EP2363484A3 (en) 1998-04-03 2012-04-25 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
WO2000009560A2 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6475718B2 (en) 1998-09-08 2002-11-05 Schering Aktiengesellschaft Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR100887482B1 (ko) 1999-01-15 2009-03-10 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
ES2569919T3 (es) 1999-04-09 2016-05-13 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ATE303445T1 (de) 1999-10-04 2005-09-15 Medicago Inc Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
AU784983B2 (en) 1999-12-15 2006-08-17 Genentech Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
WO2001049698A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
CZ20023913A3 (cs) 2000-05-03 2003-09-17 Munich Biotech Ag Kationtová diagnostická, zobrazovací a terapeutická činidla spojená s aktivovanými cévními místy
US7138501B2 (en) 2000-06-16 2006-11-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind BLyS
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
PL218428B1 (pl) 2000-10-06 2014-12-31 Kyowa Hakko Kogyo Kk Komórka, sposoby wytwarzania przeciwciał, leki zawierające przeciwciała, komórka CHO i przeciwciało klasy IgG
EP2896631A1 (en) 2000-10-10 2015-07-22 Genentech, Inc. Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
PL367324A1 (en) 2001-04-13 2005-02-21 Biogen, Inc. Antibodies to vla-1
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
US20040236080A1 (en) 2001-06-22 2004-11-25 Hiroyuki Aburatani Cell proliferation inhibitors containing anti-glypican 3 antibody
US20040161741A1 (en) 2001-06-30 2004-08-19 Elazar Rabani Novel compositions and processes for analyte detection, quantification and amplification
EP2180044A1 (en) 2001-08-03 2010-04-28 GlycArt Biotechnology AG Antibody glycosylation variants having increased anti-body-dependent cellular cytotoxicity
CN101387646B (zh) 2001-08-17 2016-08-10 建南德克公司 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
KR20100120246A (ko) 2001-11-14 2010-11-12 센토코 오르토 바이오테크 인코포레이티드 항 il-6 항체, 조성물, 방법 및 용도
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US6684637B2 (en) 2002-01-25 2004-02-03 Sunpower, Inc. Parallel slot heat exchanger
BR0307548A (pt) 2002-02-11 2006-01-17 Genentech Inc Método de produção de uma variante de anticorpo, variante de anticorpo, composição, ácido nucléico isolado, vetor, célula hospedeira, processo para a produção de uma variante de anticorpo e método de determinação do coeficiente de associação de antìgeno de um anticorpo
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization
ATE503829T1 (de) 2002-04-09 2011-04-15 Kyowa Hakko Kirin Co Ltd Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins
US7691568B2 (en) 2002-04-09 2010-04-06 Kyowa Hakko Kirin Co., Ltd Antibody composition-containing medicament
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
CA2481658A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to fcy receptor iiia
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
WO2003105757A2 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
CA2489022C (en) 2002-06-12 2012-10-16 Genencor International, Inc. Methods for improving a binding characteristic of a molecule
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US20040086979A1 (en) 2002-08-15 2004-05-06 Dongxiao Zhang Humanized rabbit antibodies
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
UA89350C2 (uk) 2002-12-16 2010-01-25 Дженентек, Інк. Гуманізоване антитіло, що зв'язує людський cd20
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
CA2515081A1 (en) 2003-02-07 2004-08-19 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
AU2004215653B2 (en) 2003-02-28 2011-03-17 Lonza Biologics Plc. Antibody purification by protein A and ion exchange chromatography
CA2517396A1 (en) 2003-02-28 2005-03-10 Antigenics Inc. Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP2272868B1 (en) 2003-06-05 2015-03-04 Genentech, Inc. Combination therapy for B cell disorders
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
CA2542125A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
ES2708095T3 (es) 2003-11-05 2019-04-08 Roche Glycart Ag Anticuerpos de CD20 con afinidad de unión a receptor de Fc y función efectora incrementadas
ME01198B (me) 2003-11-05 2013-03-20 Ares Trading Sa Prečišćavanje il-18 vezujućeg proteina
NZ547633A (en) 2003-11-06 2010-08-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP2385069A3 (en) 2003-11-12 2012-05-30 Biogen Idec MA Inc. Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
PL2418220T3 (pl) 2003-12-10 2017-12-29 E. R. Squibb & Sons, L.L.C. Przeciwciała przeciwko interferonowi alfa i ich zastosowania
BRPI0506768B1 (pt) 2004-01-09 2021-09-21 Pfizer Inc. Anticorpo monoclonal, ou fração de ligação a antígeno do mesmo que se liga especificamente a madcam,composição farmacêutica, vacina, kit de diagnostico, linhagem celular de hibridoma e método para diagnosticar in vitro um distúrbio
US20050169921A1 (en) 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
US20070116710A1 (en) 2004-02-03 2007-05-24 Leonard Bell Methods of treating hemolytic anemia
CA2555688C (en) 2004-02-11 2011-11-08 Warner-Lambert Company Llc Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
US20050260711A1 (en) 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
NZ549872A (en) 2004-04-13 2009-09-25 Hoffmann La Roche Anti-P-selectin antibodies
WO2005112564A2 (en) 2004-04-15 2005-12-01 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Germline and sequence variants of humanized antibodies and methods of making and using them
KR100620554B1 (ko) 2004-06-05 2006-09-06 한국생명공학연구원 Tag-72에 대한 인간화 항체
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
BRPI0512235A (pt) 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
EP1773391A4 (en) 2004-06-25 2009-01-21 Medimmune Inc INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
DK2213683T3 (da) 2004-08-04 2013-09-02 Mentrik Biotech Llc VARIANT-Fc-REGIONER
WO2006031825A2 (en) 2004-09-13 2006-03-23 Macrogenics, Inc. Humanized antibodies against west nile virus and therapeutic and prophylactic uses thereof
CA2580319A1 (en) 2004-09-14 2006-03-23 National Institute For Biological Standards And Control Vaccine
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ox40l抗體
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
EP2208783A1 (en) 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
EP2166018A3 (en) 2004-12-23 2010-04-28 Novo Nordisk A/S Antibody binding affinity ligands
GB0502358D0 (en) 2005-02-04 2005-03-16 Novartis Ag Organic compounds
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
PT1876236E (pt) 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
ES2659114T3 (es) 2005-08-19 2018-03-13 Wyeth Llc Anticuerpos antagonistas contra GDF-8 y usos en el tratamiento de ALS y otros trastornos asociados con GDF-8
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007060411A1 (en) 2005-11-24 2007-05-31 Ucb Pharma S.A. Anti-tnf alpha antibodies which selectively inhibit tnf alpha signalling through the p55r
CA2631212A1 (en) 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
SG172617A1 (en) 2005-12-12 2011-07-28 Ac Immune Sa Therapeutic vaccine
SI2548577T1 (sl) 2005-12-29 2017-05-31 Janssen Biotech, Inc. Človeška protitelesa proti il-23, sestavki, postopki in uporabe
NZ570802A (en) 2006-03-02 2012-03-30 Alexion Pharma Inc Prolongation of survival of an allograft by inhibiting complement activity
KR101513308B1 (ko) 2006-03-08 2015-04-28 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-c5 제제
EP4316465A3 (en) 2006-03-15 2024-04-24 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
WO2007114319A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
EP2738178A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
AU2007249408A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
JP5043008B2 (ja) 2006-06-08 2012-10-10 中外製薬株式会社 炎症性疾患の予防または治療剤
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
AU2007319576B2 (en) 2006-10-06 2014-01-16 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Prevention of tissue ischemia, related methods and compositions
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
BRPI0809105A2 (pt) 2007-03-22 2019-09-10 Novartis Ag antígenos c5 e uso destes
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
CA2691974C (en) 2007-06-29 2016-08-30 Quest Diagnostics Investments Incorporated Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry
CN101874041B (zh) 2007-09-26 2013-06-19 中外制药株式会社 抗体恒定区修饰体
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
PE20140132A1 (es) 2007-09-26 2014-02-14 Chugai Pharmaceutical Co Ltd Anticuerpo anti-receptor de il-6
CA2700986A1 (en) 2007-09-28 2009-04-02 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
CA2709354C (en) 2007-12-21 2014-06-17 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2708559B1 (en) 2008-04-11 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
EP2296573B1 (en) 2008-06-14 2019-09-25 Vytronus, Inc. System for delivering energy to tissue
SG10201405377XA (en) 2008-08-05 2014-12-30 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP3121197A1 (en) 2008-11-10 2017-01-25 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
WO2010098863A1 (en) 2009-02-26 2010-09-02 Lpath, Inc. Humanized platelet activating factor antibody design using anti-lipid antibody templates
US20110002931A1 (en) 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
CN101875696B (zh) * 2009-11-11 2012-02-08 中国人民解放军军事医学科学院生物工程研究所 一种抗体及其制备方法与应用
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
EP2528948B1 (en) 2010-01-28 2018-09-19 AB Biosciences, Inc. Novel lowered affinity antibodies and methods of making the same
AU2011223866B2 (en) 2010-03-01 2015-05-21 Alexion Pharmaceuticals Inc. Methods and compositions for treating Degos' disease
EP2545079A2 (en) 2010-03-11 2013-01-16 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
TW201206466A (en) * 2010-03-11 2012-02-16 Rinat Neuroscience Corp Antibodies with pH dependent antigen binding
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
US20140206849A1 (en) 2010-04-30 2014-07-24 Alexion Pharmaceuticals, Inc. Antibodies having reduced immunogenicity in a human
TWI654204B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
CA2822288A1 (en) 2010-12-22 2012-06-28 Medimmune, Llc Anti-c5/c5a/c5adesr antibodies and fragments
WO2012115241A1 (ja) 2011-02-25 2012-08-30 中外製薬株式会社 FcγRIIb特異的Fc抗体
SG10201509588TA (en) 2011-05-21 2015-12-30 Macrogenics Inc CD3-Binding Molecules Capable Of Binding To Human And Non-Human CD3
JP2014520148A (ja) * 2011-06-20 2014-08-21 セントルイス ユニバーシティ 治療のための神経筋接合部への標的化
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之FcRn結合域的治療性抗原結合分子
US20150299313A1 (en) 2011-10-05 2015-10-22 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
CN113416256A (zh) 2011-11-30 2021-09-21 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
JP6138108B2 (ja) 2012-02-24 2017-05-31 中外製薬株式会社 FcγRIIBを介して抗原の消失を促進する抗原結合分子
RS57414B1 (sr) 2012-03-16 2018-09-28 Regeneron Pharma Antitela sa lakim lancem konstruisanim sa histidinom i genetički modifikovani glodari za generisanje istih
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
CA2869048C (en) * 2012-03-29 2023-10-17 Novimmune S.A. Anti-tlr4 antibodies and uses thereof
TWI619729B (zh) * 2012-04-02 2018-04-01 再生元醫藥公司 抗-hla-b*27抗體及其用途
EP3892638A1 (en) 2012-05-30 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for eliminating aggregated antigens
JP6309521B2 (ja) * 2012-08-13 2018-04-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. pH依存性結合特性を有する抗PCSK9抗体
US9133269B2 (en) 2012-08-24 2015-09-15 Anaptysbio, Inc. Humanized antibodies directed against complement protein C5
TW201418707A (zh) 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分c5拮抗劑之篩選分析
CN105143261B (zh) 2013-01-31 2021-04-09 首尔大学校产学协力团 C5抗体以及用于预防和治疗补体-相关的疾病的方法
US20160032014A1 (en) 2013-03-15 2016-02-04 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
US9321686B2 (en) 2013-03-15 2016-04-26 Forta Corporation Reinforcement fiber coating compositions, methods of making and treating, and uses for improved adhesion to asphalt and portland cement concrete
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体c5を標的とする治療薬の血清半減期を増加させるための組成物及び方法
KR20210130260A (ko) 2013-04-02 2021-10-29 추가이 세이야쿠 가부시키가이샤 Fc영역 개변체
CA2920293A1 (en) 2013-08-16 2015-02-19 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
JP6382641B2 (ja) 2013-09-11 2018-08-29 株式会社東芝 非水電解質電池及び非水電解質電池の製造方法
CA2939626C (en) 2014-02-20 2023-01-17 Allergan, Inc. Complement component c5 antibodies
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
JP2016024424A (ja) 2014-07-24 2016-02-08 株式会社リコー 情報処理システム、情報処理装置、情報処理方法、及びプログラム
ES2899894T3 (es) 2014-12-19 2022-03-15 Chugai Pharmaceutical Co Ltd Anticuerpos anti-C5 y métodos de uso
WO2016117346A1 (en) 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
ES2967627T3 (es) 2015-02-27 2024-05-03 Chugai Pharmaceutical Co Ltd Composición para tratar enfermedades relacionadas con IL-6
EP3277715A2 (en) 2015-03-31 2018-02-07 Alexion Pharmaceuticals, Inc. Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
WO2016178980A1 (en) 2015-05-01 2016-11-10 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
JP2018520139A (ja) 2015-06-26 2018-07-26 アレクシオン ファーマシューティカルズ, インコーポレイテッド エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法
TW201718014A (zh) 2015-10-12 2017-06-01 諾華公司 C5抑制劑於移植相關微血管病之用途
EP3390442B1 (en) 2015-12-18 2023-11-08 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
US10233252B2 (en) 2015-12-21 2019-03-19 Wisconsin Alumni Research Foundation pH-dependent antibodies targeting the transferrin receptor and methods of use thereof to deliver a therapeutic agent
EP3402816A1 (en) 2016-01-11 2018-11-21 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment
MA53248A (fr) 2016-01-25 2022-02-16 Takeda Pharmaceuticals Co Anticorps anti-c5 à commutation ph améliorée
KR102667023B1 (ko) 2016-06-14 2024-05-21 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
TWI610941B (zh) 2016-06-17 2018-01-11 Chugai Seiyaku Kabushiki Kaisha 抗c5抗體及使用方法
CR20220563A (es) 2017-01-31 2022-12-07 Chugai Pharmaceutical Co Ltd Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
US11603406B2 (en) 2017-03-14 2023-03-14 Five Prime Therapeutics, Inc. Antibodies binding to VISTA at acidic pH
IL269134B2 (en) 2017-03-16 2024-07-01 Medimmune Ltd Antibodies against PAR2 and their use
AU2018249310A1 (en) 2017-04-03 2019-10-17 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
BR112020008182A2 (pt) 2017-10-26 2020-10-27 Alexion Pharmaceuticals, Inc. dosagem e administração de anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna (hpn) e síndrome hemolítica urêmica atípica (shua)
MX2020005547A (es) 2017-12-04 2020-08-20 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
TWI704157B (zh) 2018-08-01 2020-09-11 日商中外製藥股份有限公司 在c5相關疾病之治療或預防中使用的醫藥組成物與治療或預防c5相關疾病的方法

Also Published As

Publication number Publication date
PH12017501114A1 (en) 2017-11-27
US20240052021A1 (en) 2024-02-15
TWI725847B (zh) 2021-04-21
JP6755217B2 (ja) 2020-09-16
EP3233921B1 (en) 2021-09-29
PT3233921T (pt) 2021-12-09
BR112017011235A2 (pt) 2018-02-06
US10023630B2 (en) 2018-07-17
KR101838645B1 (ko) 2018-03-14
ZA201703241B (en) 2025-12-17
SI3233921T1 (sl) 2022-01-31
TW201632557A (zh) 2016-09-16
EA201791366A1 (ru) 2018-02-28
EP3233921A1 (en) 2017-10-25
CN113045650A (zh) 2021-06-29
CR20170251A (es) 2017-07-19
US20160176954A1 (en) 2016-06-23
RU2017125758A3 (es) 2019-10-25
RS62749B1 (sr) 2022-01-31
US20200031913A1 (en) 2020-01-30
US9765135B2 (en) 2017-09-19
US20190062413A1 (en) 2019-02-28
US11597760B2 (en) 2023-03-07
SG10201710322VA (en) 2018-02-27
KR20230044338A (ko) 2023-04-03
LT3233921T (lt) 2021-12-10
TWI617580B (zh) 2018-03-11
CO2017006651A2 (es) 2017-09-29
RU2746356C2 (ru) 2021-04-12
EP3981794A1 (en) 2022-04-13
CL2021000630A1 (es) 2021-07-30
CN107207607A (zh) 2017-09-26
KR102515796B1 (ko) 2023-03-30
SG11201607165YA (en) 2016-09-29
PH12017501114B1 (en) 2023-12-06
KR20180029267A (ko) 2018-03-20
EP3233921A4 (en) 2018-07-11
HUE056489T2 (hu) 2022-02-28
JP2017509312A (ja) 2017-04-06
RU2017125758A (ru) 2019-01-22
HRP20211934T1 (hr) 2022-03-18
AU2015365167A1 (en) 2017-06-01
JP2017200489A (ja) 2017-11-09
TW201809008A (zh) 2018-03-16
PL3233921T3 (pl) 2022-01-10
US20180002415A1 (en) 2018-01-04
AU2015365167B2 (en) 2021-07-29
MX384138B (es) 2025-03-14
WO2016098356A1 (en) 2016-06-23
MY183415A (en) 2021-02-18
TW202031897A (zh) 2020-09-01
JP6174782B2 (ja) 2017-08-02
KR20170092449A (ko) 2017-08-11
UA128712C2 (uk) 2024-10-09
MX2017007616A (es) 2017-09-18
CN107207607B (zh) 2021-05-04
CA2967554A1 (en) 2016-06-23
CL2017001585A1 (es) 2018-12-21
US10385122B2 (en) 2019-08-20
ES2899894T3 (es) 2022-03-15

Similar Documents

Publication Publication Date Title
AR103162A1 (es) Anticuerpos anti-c5 y métodos para su uso
MX2023001360A (es) Anticuerpos anti-c5 y metodos de uso.
CO2018007374A2 (es) Anticuerpos anti-c5 y métodos de uso
AR103161A1 (es) Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
AR113342A1 (es) Anticuerpos específicos cd47 / pd-l1
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
MX2015009594A (es) Construcciones de anticuerpos para cdh19 y cd3.
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
MX2017007187A (es) Construcciones de anticuerpos de adn y metodo para utilizarlas.
BR112017003582A2 (pt) anticorpos, composições e usos
AR082518A1 (es) Anticuerpos contra il-18r1 y usos de los mismos
MX2017012834A (es) Anticuerpos anti-c1s humanizados y metodos para usarlos.
AR115695A1 (es) Moléculas proteicas multifuncionales que comprenden decorina y uso de estas
PE20190415A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos
AR099604A1 (es) Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso
AR094598A1 (es) Construcciones de anticuerpos para cdh19 y cd3

Legal Events

Date Code Title Description
FG Grant, registration